• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of cellular physiology. >Single peptides and combination modalities for triple negative breast cancer
【24h】

Single peptides and combination modalities for triple negative breast cancer

机译：单肽和组合形式三阴性乳腺癌

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Unlike other types of breast cancers (BCs), no specific therapeutic targets have been established for triple negative breast cancer (TNBC). Therefore, chemotherapy and radiotherapy are the only available adjuvant therapeutic choices for TNBC. New emerging reports show that TNBC is associated with higher numbers of intratumoral tumor infiltrating lymphocytes. This is indicative of host anti-TNBC immune surveillance and suggesting that immunotherapy can be considered as a therapeutic approach for TNBC management. Recent progress in molecular mechanisms of tumor-immune system interaction and cancer vaccine development studies, fast discoveries and FDA approvals of immune checkpoint inhibitors, chimeric antigen receptor T-cells, and oncolytic virotherapy have significantly attracted attention and research directions toward the immunotherapeutic approach to TNBC. Here in this review different aspects of TNBC immunotherapies including the host immune system-tumor interactions, the tumor microenvironment, the relevant molecular targets for immunotherapy, and clinical trials in the field are discussed.
机译：与其他类型的乳腺癌(BCs),没有具体的治疗目标建立了三阴性乳腺癌(TNBC)。是唯一可用的辅助治疗对TNBC的选择。TNBC的关联瘤内肿瘤浸润淋巴细胞。表明主机anti-TNBC免疫监测和表明免疫疗法可以认为是一个治疗方法TNBC的管理。肿瘤免疫系统相互作用和机制癌症疫苗开发研究、快发现和FDA批准的免疫检查点抑制剂,嵌合抗原受体t细胞和溶瘤病毒治疗极大地吸引了关注和研究方向朝免疫治疗方法TNBC。TNBC免疫疗法包括宿主的免疫系统的交互,肿瘤微环境,相关的分子靶点免疫治疗和临床试验领域进行了讨论。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号